FAST RESULTS. FOCUSED DELIVERY.

Help your patients with mild-to-moderate plaque psoriasis show their unexpected with the proven power of SERNIVO® Spray.1

FAST RESULTS

Investigator’s Global Assessment of treatment success2,a

Patents who achieved a ≥50% reduction in Total Sign Score (TSS50)2,3,a

Patient-reported itching decreased by approximately 50% at day 42,b

*Primary endpoint; **Secondary endpoint.

aPooled data based on results from 2 randomized, controlled studies of adults with moderate plaque psoriasis with similar methodology. Subjects were randomized to either SERNIVO (n=356), diprolene lotion (n=90), or vehicle (n=182).
Treatment success was defined as an Investigator’s Global Assessment (IGA) of 0 or 1 (clear or almost clear) and at least a 2-grade reduction from baseline.2,3

bItching was assessed proactively using Fisher’s exact test, with subjects asked if they were experiencing itching (yes/no) at each visit (days 4, 8, 15, and 29) or had experienced itching since their last visit (post-hoc analysis).4

FOCUSED FORMULATION

SERNIVO is designed to target the skin layers where plaques occur, with limited absorption into the bloodstream.5

SERNIVO is formulated for balance, providing high penetration in the epidermis and dermis,
with low systemic absorption.5,c

cOf several prototype formulations tested in vitro, SERNIVO provided the best balance of high penetration/permeation and low absorption.5

VERSATILE
APPLICATION

SERNIVO can be used for hard-to-reach plaques on the back, in addition to hard-to-treat elbows and knees, and hairy areas.d

  • Can be sprayed in any direction, including
    upside down
  • Is nongreasy6 and may provide a patient-friendly treatment experience
  • Can be easily applied to both large and small plaques on the body

dAvoid use on the face, scalp, axilla, groin, or other intertriginous areas.

PATIENT SAVINGS

With the SERNIVO Patient Savings Program, eligible patients can save on their SERNIVO prescription. Eligible patients pay
as little as $0.

IMPORTANT SAFETY INFORMATION

SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing’s syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings. Avoid use on the face, scalp, axilla, groin or other intertriginous areas. Use of SERNIVO Spray is not recommended in pediatric patients as they are more susceptible to systemic toxicity. Allergic contact dermatitis may occur. The most common adverse reactions (≥1%) were application site pruritus, burning and/or stinging, pain, and atrophy. Local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. These are not all the possible side effects of SERNIVO Spray.
Please refer to Full Prescribing Information.

INDICATION AND USAGE

SERNIVO Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.

To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at
1-800-FDA-1088.

References: 1. SERNIVO Prescribing Information. Promius Pharma, LLC. Princeton, NJ. February 2016.
2. Gold LS, Jackson JM, Knuckles MLF, Weiss JS. Improvement in extensive moderate plaque psoriasis with a novel emollient spray formulation of betamethasone dipropionate 0.05%. J Drugs Dermatol. 2016;15(3):334-342. 3. Gold LS, Pariser D, Jackson JM. DFD-01, a midpotent betamethasone dipropionate 0.05% in an emollient-like spray formulation demonstrates similar efficacy to a super potent topical steroid for the treatment of moderate plaque psoriasis. Poster presented at: Annual Fall Dermatology Conference; November 3-6, 2016; Las Vegas, NV. 4. Zirwas M, Hebert A. Fast relief of itching in psoriasis with DFD-01, a novel medium-potency emollient spray formulation of betamethasone dipropionate 0.05%. Poster presented at: Winter Clinical Dermatology Conference; January 13-18, 2017; Kona, HI. 5. Kircik L, Okumu F, Kandavilli S, Sugarman J. Rational vehicle design ensures targeted cutaneous steroid delivery.
J Clin Aesthet Dermatol. 2017;10(2):12-19. 6. US Food and Drug Administration NDA # 208079. Dr. Reddy’s Laboratories, Princeton, NJ: Feb 2016.
IMPORTANT SAFETY INFORMATION
SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing's syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-poten cy topical corticosteroids..
IMPORTANT SAFETY INFORMATION
SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing's syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-poten cy topical corticosteroids..